American Journal of Cardiology
Volume 106, Issue 8 , Pages 1124-1128, 15 October 2010

Prevalence and Spectrum of Large Deletions or Duplications in the Major Long QT Syndrome-Susceptibility Genes and Implications for Long QT Syndrome Genetic Testing

  • David J. Tester, BS

      Affiliations

    • Departments of Medicine, Pediatrics, and Molecular Pharmacology and Experimental Therapeutics/Divisions of Cardiovascular Diseases and Pediatric Cardiology/Windland Smith Rice Sudden Death Genomics Laboratory, Rochester, Minnesota
  • ,
  • Amber J. Benton, BS

      Affiliations

    • Departments of Medicine, Pediatrics, and Molecular Pharmacology and Experimental Therapeutics/Divisions of Cardiovascular Diseases and Pediatric Cardiology/Windland Smith Rice Sudden Death Genomics Laboratory, Rochester, Minnesota
  • ,
  • Laura Train, BS

      Affiliations

    • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
  • ,
  • Barbara Deal, MD

      Affiliations

    • Division of Cardiology, Children's Memorial Hospital, Chicago, Illinois
  • ,
  • Linnea M. Baudhuin, PhD

      Affiliations

    • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
  • ,
  • Michael J. Ackerman, MD, PhD

      Affiliations

    • Departments of Medicine, Pediatrics, and Molecular Pharmacology and Experimental Therapeutics/Divisions of Cardiovascular Diseases and Pediatric Cardiology/Windland Smith Rice Sudden Death Genomics Laboratory, Rochester, Minnesota
    • Corresponding Author InformationCorresponding author: Tel: 507-284-0101; fax: 507-284-3757

Received 16 March 2010; received in revised form 2 June 2010; accepted 2 June 2010. published online 01 September 2010.

Long QT syndrome (LQTS) is a cardiac channelopathy associated with syncope, seizures, and sudden death. Approximately 75% of LQTS is due to mutations in genes encoding for 3 cardiac ion channel α-subunits (LQT1 to LQT3). However, traditional mutational analyses have limited detection capabilities for atypical mutations such as large gene rearrangements. We set out to determine the prevalence and spectrum of large deletions/duplications in the major LQTS-susceptibility genes in unrelated patients who were mutation negative after point mutation analysis of LQT1- to LQT12-susceptibility genes. Forty-two unrelated, clinically strong LQTS patients were analyzed using multiplex ligation-dependent probe amplification, a quantitative fluorescent technique for detecting multiple exon deletions and duplications. The SALSA multiplex ligation-dependent probe amplification LQTS kit from MRC-Holland was used to analyze the 3 major LQTS-associated genes, KCNQ1, KCNH2, and SCN5A, and the 2 minor genes, KCNE1 and KCNE2. Overall, 2 gene rearrangements were found in 2 of 42 unrelated patients (4.8%, confidence interval 1.7 to 11). A deletion of KCNQ1 exon 3 was identified in a 10-year-old Caucasian boy with a corrected QT duration of 660 ms, a personal history of exercise-induced syncope, and a family history of syncope. A deletion of KCNQ1 exon 7 was identified in a 17-year-old Caucasian girl with a corrected QT duration of 480 ms, a personal history of exercise-induced syncope, and a family history of sudden cardiac death. In conclusion, because nearly 5% of patients with genetically elusive LQTS had large genomic rearrangements involving the canonical LQTS-susceptibility genes, reflex genetic testing to investigate genomic rearrangements may be of clinical value.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr. Ackerman received support from the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program, Rochester, Minnesota, and Grant HD42569 from the National Institutes of Health, Bethesda, Maryland.

PII: S0002-9149(10)01209-9

doi:10.1016/j.amjcard.2010.06.022

American Journal of Cardiology
Volume 106, Issue 8 , Pages 1124-1128, 15 October 2010